What is William Blair’s Forecast for Biodesix Q1 Earnings?

Biodesix, Inc. (NASDAQ:BDSX) – Equities researchers at William Blair issued their Q1 2025 earnings per share (EPS) estimates for shares of Biodesix in a research note issued to investors on Tuesday, March 4th. William Blair analyst A. Brackmann anticipates that the company will earn ($0.08) per share for the quarter. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Biodesix’s current full-year earnings is ($0.35) per share. William Blair also issued estimates for Biodesix’s Q2 2025 earnings at ($0.06) EPS, Q3 2025 earnings at ($0.05) EPS, Q4 2025 earnings at ($0.03) EPS and FY2025 earnings at ($0.22) EPS.

Biodesix (NASDAQ:BDSX) last posted its quarterly earnings results on Monday, March 3rd. The company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.01. The company had revenue of $20.43 million for the quarter, compared to the consensus estimate of $19.92 million. Biodesix had a negative return on equity of 275.79% and a negative net margin of 66.84%.

Biodesix Stock Performance

BDSX stock opened at $0.87 on Thursday. The business’s fifty day moving average is $1.09 and its 200-day moving average is $1.41. The company has a quick ratio of 3.40, a current ratio of 3.40 and a debt-to-equity ratio of 1.30. The company has a market cap of $126.56 million, a P/E ratio of -2.23 and a beta of 1.10. Biodesix has a twelve month low of $0.64 and a twelve month high of $2.04.

Institutional Trading of Biodesix

A number of large investors have recently made changes to their positions in BDSX. Wilmington Savings Fund Society FSB bought a new stake in shares of Biodesix in the 3rd quarter valued at $10,849,000. Samjo Management LLC bought a new stake in shares of Biodesix in the 4th quarter valued at $3,790,000. Susquehanna International Group LLP increased its position in shares of Biodesix by 769.8% in the 4th quarter. Susquehanna International Group LLP now owns 1,115,748 shares of the company’s stock valued at $1,707,000 after buying an additional 987,475 shares in the last quarter. Silverarc Capital Management LLC increased its holdings in Biodesix by 21.7% during the 4th quarter. Silverarc Capital Management LLC now owns 4,332,281 shares of the company’s stock worth $6,628,000 after purchasing an additional 771,187 shares in the last quarter. Finally, AIGH Capital Management LLC increased its holdings in Biodesix by 8.8% during the 4th quarter. AIGH Capital Management LLC now owns 6,179,812 shares of the company’s stock worth $9,455,000 after purchasing an additional 500,000 shares in the last quarter. Institutional investors own 20.96% of the company’s stock.

Insider Activity

In related news, CEO Scott Hutton sold 83,660 shares of the company’s stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $0.92, for a total value of $76,967.20. Following the completion of the sale, the chief executive officer now owns 701,947 shares in the company, valued at $645,791.24. This represents a 10.65 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders have sold a total of 128,702 shares of company stock valued at $118,406 in the last 90 days. 69.20% of the stock is owned by company insiders.

About Biodesix

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.